US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman
  
The FDA's review operations stayed on track despite the challenging environment in Q1 2025. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Geography